ESR1 and female reproductive organ cancer: C10orf116/APM2 expression has been implicated in other gynecological cancers; for instance, is has been shown to strongly differentiate between the BRCA1 associated breast tumor subclasses ESR1-positive and ESR1-negative [20] and is has been found to be downregulated in utering cancer in a number of studies [21].